venlafaxine

(redirected from Effexor XR)
Also found in: Dictionary.

venlafaxine

 [ven″lah-fak´sēn]
an inhibitor of serotonin and norepinephrine uptake that stimulates neurotransmitter activity in the central nervous system; administered orally as the hydrochloride salt as an antidepressant and antianxiety agent.

venlafaxine

/ven·la·fax·ine/ (ven″lah-fak´sēn) an inhibitor of serotonin and norepinephrine reuptake that potentiates neurotransmitter activity in the central nervous system; used as the hydrochloride salt as an antidepressant and antianxiety agent.

venlafaxine

(vĕn′lə-făk′sēn, -sĭn)
n.
A drug of the SNRI class, C17H27NO2, used in its hydrochloride form to treat depression and anxiety.

venlafaxine

Effexor® Neuropharmacology A second-generation bicyclic member of the serotonin-norepinephrine reuptake inhibitor class of antidepressants. See Paxil, Prozac, Zoloft.

venlafaxine

A SEROTONIN and NORADRENALINE re-uptake inhibitor drug used to treat depression. Brand names are Efexor and Efexor XL.
References in periodicals archive ?
Effexor XR Wyeth-Ayerst Antidepressant (serotonin/ norepinephrine reuptake inhibitor) 14.
In other countries (eg, South Africa), the generic Effexor XR came out even earlier and one generic company, Ciplo Medpro [9] , are already legally manufacturing and selling extended release venlafaxine capsules under the brand name Venlor XR in that country.
In the study, 69 percent or more of patients treated with Effexor XR showed significant improvements in symptoms of GAD for up to six months, compared with 42 to 46 percent given a placebo.
The most common adverse events reported in EFFEXOR XR short-term placebo-controlled depression trials and EFFEXOR XR short-term placebo-controlled depression, generalized anxiety disorder (GAD), and/or social anxiety disorder trials (incidence greater than or equal to 10% and greater than or equal to 2x that of placebo) were anorexia, asthenia, constipation, dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea, nervousness, somnolence, and sweating.
The two randomized, double-blind, placebo-controlled trials evaluated the short- and long-term efficacy and safety of Effexor XR in treating symptoms of GAD.
During Jim's tenure leading Wyeth Canada, sales more than doubled to over $650 million in less than four years, and all key promoted brands including Effexor XR, Prevnar, Enbrel, Alesse, Premarin and BeneFix achieved the #1 market share position in each of their respective categories.
Prescriptions for venlafaxine "should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose," according to the revised label or prescribing information for Effexor and Effexor XR.
The study was funded by Wyeth Research, the parent company of which distributes venlafaxine XR under the brand name Effexor XR.
The trial was funded by Wyeth Research, which markets Effexor XR.
The depression therapeutics market will face the patent expiry of leading drugs such as Lexapro (2012), Cymbalta (2013) and Effexor XR (2014).
The Pharmacor advisory service entitled Unipolar Depression finds that major-market sales in the unipolar depression market will decline by 30 percent from 2012-2022 owing to the generic entry of the blockbuster drugs escitalopram (Lundbeck's Cipralex/Seroplex, other manufacturers, Forest Laboratories' Lexapro, generics; Lundbeck/Mochida Pharmaceuticals/Mitsubishi Tanabe Pharma's Lexapro), Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Eli Lilly/Shionogi's Cymbalta/Xeristar, as well as expanded generic competition for venlafaxine XR (Pfizer/Almirall's Effexor XR, other manufacturers, generics).
All 33 randomized trials and the pooled analysis were funded by Wyeth Pharmaceuticals, which markets venlafaxine as Effexor XR.